Lifecore Biomedical, INC \de\ Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Legion Partners, through various entities, has increased its beneficial ownership of Lifecore Biomedical, Inc. to 17.1%, signaling a significant investment and potential strategic interest.
NASDAQ
22NW Fund has initiated a redemption process for its Series A Preferred Stock in Lifecore Biomedical, signaling a significant shift in its investment.
NASDAQ
SCHEDULE 13D/A: 22NW Fund Reduces Stake in Lifecore Biomedical to 7.49% Following Significant Share Sales
22NW Fund, LP, a major investor in Lifecore Biomedical, Inc., has reduced its beneficial ownership to 7.49% of the company's common stock after selling over 1.49 million shares in the open market.